A5064885323- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Nutritional Studies and Diet
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Brain Metastases and Treatment
- Cancer, Lipids, and Metabolism
- Nutrition, Genetics, and Disease
- BRCA gene mutations in cancer
- Acute Myeloid Leukemia Research
- Genetic factors in colorectal cancer
- Cancer Risks and Factors
- Heat shock proteins research
- Radiopharmaceutical Chemistry and Applications
- Metabolism, Diabetes, and Cancer
- PARP inhibition in cancer therapy
- CNS Lymphoma Diagnosis and Treatment
- Menopause: Health Impacts and Treatments
- Estrogen and related hormone effects
- Management of metastatic bone disease
- Ferroptosis and cancer prognosis
- Lung Cancer Research Studies
- Male Breast Health Studies
Oncology Hematology Care
2023-2025
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2021-2024
The Ohio State University
2017-2024
The Ohio State University Wexner Medical Center
2019-2023
Ohio University
2020-2021
Indiana University Health
2015
Indiana University – Purdue University Indianapolis
2015
Roswell Park Comprehensive Cancer Center
2012
The University of Texas MD Anderson Cancer Center
2009-2011
Wayne State University
1973
The pivotal phase III ASCENT trial demonstrated improved survival outcomes associated with sacituzumab govitecan (SG), an anti-trophoblast cell-surface antigen 2 (anti-Trop-2) antibody-drug conjugate linked the topoisomerase-inhibitor SN-38, over single-agent chemotherapy treatment of physician's choice (TPC) in previously treated metastatic triple-negative breast cancer (mTNBC). This prespecified, exploratory biomarker analysis from evaluates association between tumor Trop-2 expression and...
Patients with cancer often experience comorbidities that may affect their prognosis and outcome. The objective of this study was to determine the effect on survival patients myelodysplastic syndrome (MDS).We conducted a retrospective cohort 600 consecutive MDS who presented MD Anderson Cancer Center from January 2002 December 2004. Adult Comorbidity Evaluation-27 (ACE-27) scale used assess comorbidities. Data demographics, International Prognostic Scoring System (IPSS), treatment, outcome...
Abstract Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we report results from dose escalation 2 expansion cohorts: Module 1A paired biopsy cohort solid tumor patients, 1B-1 triple negative breast cancer (TNBC) monotherapy expansion, 2A fulvestrant combination HR+/HER2− post-CDK4/6-inhibitor. Core primary...
Abstract Purpose Sacituzumab govitecan (SG) is an antibody–drug conjugate composed of anti–Trop-2 antibody coupled to SN-38 via a proprietary hydrolyzable linker. In the ASCENT study, SG improved survival versus single-agent treatment physician’s choice (TPC) in pre-treated metastatic triple-negative breast cancer (mTNBC). Hormone/HER2 receptor changes are common, particularly at relapse/metastasis. This subanalysis assessed outcomes patients who did/did not have TNBC initial diagnosis,...
Abstract Purpose: Fatty acid synthase (FASN) is overexpressed in 70% of operable triple-negative breast cancer (TNBC) and associated with poor prognosis. Proton pump inhibitors selectively inhibit FASN activity induce apoptosis TNBC cell lines. Patients Methods: were enrolled this single-arm phase II study. began omeprazole 80 mg orally twice daily for 4–7 days prior to neoadjuvant anthracycline–taxane-based chemotherapy (AC-T) continued until surgery. The primary endpoint was pathologic...
"HSR25-154: Treatment Patterns and Prognosis of Patients With HER2-Negative Early Breast Cancer Germline Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2 PALB2" published on 28 Mar 2025 by National Comprehensive Network.
The objective of this pilot study was to evaluate the change in sexual function following treatment with fractional CO2 laser therapy breast cancer (BC) survivors genitourinary syndrome menopause (GSM).A single-arm feasibility BC symptoms GSM, including dyspareunia and/or vaginal dryness, conducted. Participants who received three treatments and 4-week follow-up were contacted for patient-reported outcomes adverse events at 12 months. Sexual measured using Female Function Index (FSFI)...
We evaluated associations of the Empirical Dietary Index for Hyperinsulinemia (EDIH), Inflammatory Pattern (EDIP) and Healthy Eating (HEI2015) their metabolomics profiles with risk total site-specific cancers. used baseline food frequency questionnaires to calculate dietary scores among 112,468 postmenopausal women in Women's Health Initiative. multivariable-adjusted Cox regression estimate hazard ratios (HR) 95% confidence intervals cancer estimation. Metabolomic profile were derived using...
Abstract Background: ctDNA monitoring during adjuvant endocrine therapy provides an opportunity to detect molecular relapse before clinically apparent recurrence. The rate and dynamics of positivity the frequency asymptomatic but imaging detectable metastatic disease at time detection remain unknown in high-risk ER+/HER2- breast cancers. We present results rates 508 ctDNA+ patients from a prospective, multicenter, randomized surveillance intervention trial, DARE (NCT04567420). Patients...
(1) Background: The objective of this study was to determine the long-term efficacy fractional CO2 laser therapy in breast cancer survivors. (2) Methods: This a single-arm Participants received three treatments and returned for 4 week follow-up. were contacted follow-up at annual intervals. Vaginal Assessment Scale (VAS), Female Sexual Function Index (FSFI), Distress Scare Revised (FSDS-R), Urinary Inventory (UDI), adverse events collected reported two-year changes scores compared between...
Abstract Background Triple-negative breast cancer (TNBC) is a heterogeneous disease and we have previously shown that rapid relapse of TNBC associated with distinct sociodemographic features. We hypothesized versus late in also defined by clinical genomic features primary tumors. Methods Using three publicly-available datasets, identified 453 patients diagnosed adequate follow-up to be characterized as ‘rapid relapse’ (rrTNBC; distant or death ≤2 years diagnosis), ‘late (lrTNBC; > 2...
PURPOSE To evaluate the impact of targeted DNA sequencing on selection cancer therapy for patients with metastatic breast (MBC). PATIENTS AND METHODS In this prospective, single-center, single-arm trial, MBC were enrolled within 10 weeks starting a new therapy. At enrollment, tumor samples underwent next-generation any 315 cancer-related genes to high depth (> 500×) using FoundationOne CDx. Sequencing results released providers at time disease progression, and physician treatment...
While combinations of immune checkpoint (ICP) inhibitors and neo-adjuvant chemotherapy (NAC) have begun testing in patients with breast cancer (BC), the effects on ICP expression circulating T cells within tumor microenvironment are still unclear. This information could help design future clinical trials by permitting selection most appropriate for incorporation into NAC.Peripheral blood samples and/or specimens before after NAC were obtained from 24 women operable BC. The CTLA4, PD-1, Lag3,...
Inflammatory breast cancer (IBC) poses an ongoing challenge as rates of disease recurrence and mortality remain high compared to stage-matched controls. However, frontline therapy has evolved through the years, including widespread use neoadjuvant chemotherapy (NAC) given prognostic importance pathologic complete response (pCR). Due these sweeping changes, we need new data assess current survival outcomes for locally advanced IBC in context matched non-inflammatory We conducted a...
Abstract There is limited data regarding the added benefit of adjuvant systemic therapy in management small, node-negative, HER2+ breast cancer. In a multi-institutional retrospective analysis using American Society Clinical Oncology CancerLinQ database, we compared survival outcomes among T1a-c N0 patients diagnosed between 2010 to 2021 who received locoregional alone or combination with trastuzumab (+/− chemotherapy). Primary were invasive disease-free (iDFS) and overall (OS). Of 1,184...